To the full analysis
Takeda Pharmaceutical stock: dividend
TAKTakeda Pharmaceutical paid $0.71 per share over the last twelve months, 3.34% on the price, and has not cut its dividend for 5 years.
Daily figure as of 13 Nov 2026
Dividend yield over the last 12 months
3.34%
$0.71 per share over 12 months
Dividend per share 2025
$0.62
paid in fiscal 2025
no data
$1.25
covers the dividend of $0.62
Raised in a row
1 year
Years with a higher annual dividend than the year before
Growth 5 years
−2.6%
per year, from the last twelve months, without special dividends
Growth 10 years
−1.6%
per year, from the last twelve months, without special dividends
The yield is based on the dividends per security over the last 12 months and today's price. The figures for fiscal year 2025 come from the financial statements. For this security they are in a different currency than the price or apply per ordinary share, and with an ADR one security can stand for several shares. The two figures therefore cannot be compared directly.
Dividend dates and payments
Anyone holding the stock on the day before the ex-dividend date receives the dividend. Amounts are per share, before tax.
Last ex-dividend date
29 Sep 2026
$0.3970
Next ex-dividend date
not announced yet
Frequency
semi-annual
All 10 payments of the last five years
| Ex-dividend date | Payment date | Dividend per share |
|---|---|---|
| 29 Sep 2026 | no data | $0.3970 |
| 31 Mar 2026 | 6 Jul 2026 | $0.3083 |
| 30 Sep 2025 | 11 Dec 2025 | $0.3221 |
| 31 Mar 2025 | 7 Jul 2025 | $0.2760 |
| 30 Sep 2024 | 12 Dec 2024 | $0.3261 |
| 27 Mar 2024 | 8 Jul 2024 | $0.2922 |
| 28 Sep 2023 | 11 Dec 2023 | $0.3191 |
| 30 Mar 2023 | 10 Jul 2023 | $0.3100 |
| 29 Sep 2022 | 12 Dec 2022 | $0.3296 |
| 30 Mar 2022 | 11 Jul 2022 | $0.3301 |
Dividend development
Dividend per share
Payout ratio
- of earnings
- of free cash flow
Figures as a table
| Year | Dividend per share | Earnings per share |
|---|---|---|
| 2006 | $0.36 | $0.60 |
| 2007 | $0.48 | $0.66 |
| 2008 | $0.55 | $0.45 |
| 2009 | $0.57 | $0.59 |
| 2010 | $0.56 | $0.49 |
| 2011 | $0.56 | $0.25 |
| 2012 | $0.56 | $0.29 |
| 2013 | $0.56 | $0.21 |
| 2014 | $0.56 | −$0.15 |
| 2015 | $0.57 | $0.16 |
| 2016 | $0.57 | $0.23 |
| 2017 | $0.57 | $0.37 |
| 2018 | $0.47 | $0.22 |
| 2019 | $0.57 | $0.09 |
| 2020 | $0.57 | $0.75 |
| 2021 | $0.57 | $0.46 |
| 2022 | $0.56 | $0.64 |
| 2023 | $0.57 | $0.29 |
| 2024 | $0.59 | $0.21 |
| 2025 | $0.62 | −$0.30 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.